Vitronectin shows complement-independent binding to isolated keratin filament aggregates.
Keratinocyte cell death, whether produced by skin disease or by physiologic apoptosis in normal skin, may result in formation of dermal keratin bodies, consisting mainly of keratin intermediate filament aggregates. Vitronectin, a multifunctional plasma and tissue glycoprotein, which inhibits the complement membrane attack complex and promotes cell attachment and spreading, is, like amyloid P component, associated with keratin bodies in vivo. To investigate a potential role for vitronectin in the removal of keratin bodies, we studied the interaction of vitronectin with keratin intermediate filaments in normal human skin and in Hep-2 cells, as well as with isolated keratin intermediate filament aggregates in vitro. Following pre-incubation of skin sections and Hep-2 cells with normal human serum (as a source of vitronectin), cytoplasmic staining of keratinocytes and of cytoskeletal filaments in Hep-2 cells was observed by immuno-fluorescence staining with polyclonal and monoclonal anti-vitronectin antibodies. Vitronectin binding to keratin intermediate filament aggregates extracted from normal human epidermis was demonstrated by immunofluorescence and by immunoblotting, and was not dependent on complement activation, because it occurred even when heat-inactivated human serum or C4-deficient serum was used as a source of vitronectin. Amyloid P component shows Ca++- dependent binding to keratin intermediate filament aggregates. does not involve amyloid P component because it occurred when binding of the latter protein was inhibited by EDTA buffer. Moreover, purified vitronectin also bound to keratin intermediate filament aggregates in immunofluorescence studies. Vitronectin binding to keratin intermediate filaments may play a role both in limiting complement-mediated tissue damage (because keratin bodies may activate complement) and in promoting removal of keratin bodies by fibroblasts and/or macrophages.
Hintner
H
H
Department of Dermatology, University of Innsbruck, Austria.
Stanzl
U
U
Dahlbäck
K
K
Dahlbäck
B
B
Breathnach
S M
SM
D015153:Blotting, Western; D002478:Cells, Cultured; D003165:Complement System Proteins / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007382:Intermediate Filaments / Q000378:metabolism*; D015603:Keratinocytes / Q000378:metabolism; D007633:Keratins; D008970:Molecular Weight; D000683:Serum Amyloid P-Component / Q000378:metabolism; D019096:Vitronectin
D006023:Glycoproteins; D000683:Serum Amyloid P-Component; D019096:Vitronectin; D007633:Keratins; D003165:Complement System Proteins